Comparison · NCT04575038-f6c6ad22
Standard of Care + Brequinar 100 mg vs Standard of Care + Placebo: Hospital Admission
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Standard of Care + Brequinar 100 mg vs Standard of Care + Placebo: Hospital Admission. Trial comparisons, record NCT04575038-f6c6ad22. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04575038-f6c6ad22
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0179 | 0.00316 | 0.0945 | wilson | |
| Risk in group 2 | 0 | 0 | 0.0611 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0179 | -0.045 | 0.0945 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | log | a group has no participants with the outcome | |||
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat, for one more participant with the outcome on Standard of Care + Brequinar 100 mg than on Standard of Care + Placebo | 56 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Standard of Care + Brequinar 100 mg | Standard of Care + Brequinar oral capsules 100 mg x 5 days~Brequinar: Dihydroorotate dehydrogenase inhibitor (DHODHi) | 1 | 56 | OG000 |
| Group 2 | Standard of Care + Placebo | Standard of Care + Placebo for Brequinar oral capsules x 5 days~Placebo: Placebo capsules | 0 | 59 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Hospital Admission
- Description
- Percentage of subjects requiring admission as an inpatient for \>24 hours
- Time frame
- Day 29
- Population
- Intent-to-treat population
Source ClinicalTrials.gov
Trial
- Title
- CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19
- NCT number
- NCT04575038
- Phases
- PHASE2
- Conditions
- COVID-19 Infection
- Interventions
- Brequinar, Placebo
- Lead sponsor
- Clear Creek Bio, Inc.
- Results first posted
- 2022-04-19
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04575038?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04575038-f6c6ad22